

BEST AVAILABLE COPY



PCT/EP200 4 / 0 0 7 2 5 3

02 07 2004



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D - 5 AUG 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 29 April 2004

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



- 4 JUL 2003

The
Patent
Office

1 / 77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales NP10 8QQ

1.	Your reference	OP/4-33272P1		
2.	Patent application number (The Patent Office will fill in this part)	0315745.0		04 JUL 2003 5JUL03 E820371-1 D01011 P01/7700 0.00-0315745.0
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	NOVARTIS AG LICHTSTRASSE 35 4056 BASEL SWITZERLAND 7125487005 SWITZERLAND		
	Patent ADP number (if you know it)			
	If the applicant is a corporate body, give the country/state of its incorporation			
4.	Title of invention	Organic compounds		
5.	Name of your agent (if you have one)	Craig McLean		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Novartis Pharmaceuticals UK Limited Patents and Trademarks Wimblehurst Road Horsham, West Sussex RH12 5AB		
	Patents ADP number (if you know it)	7181522002		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:	Yes		
	a) any applicant named in part 3 is not an inventor, or			
	b) there is an inventor who is not named as an applicant, or			
	c) any named applicant is a corporate body.			
	(see note (d))			

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 12 ✓

Claim(s) 2 ✓

Abstract 1 ✓

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)


Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date



4th July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. S. Schnerr

01403 323069

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Organic Compounds

The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.

The synthesis of peranhydrocyclodextrins was described as from 1991 (Gadelle A. and Defaye J., *Angew. Chem. Int. Ed. Engl.*, (1991), 30, 78-79; Ashton P. R., Ellwood P., Staton I. and Stoddart J. F. *Angew. Chem. Int. ed. Engl.*, (1991) 30, 80-81) and the authors describe that these derivatives have interesting solubilities both in water and in organic solvents.

As used herein, peranhydrocyclodextrins refer to per(3,6-anhydro)cyclodextrins, wherein the cyclodextrin may be alpha, beta or gamma or a mixture thereof, and wherein each molecule contains at least five 3,6-anhydro-glucopyranose units. Representative examples of said peranhydrocyclodextrins are hexakis(3,6-anhydro)- α -cyclodextrin, heptakis(3,6-anhydro)- β -cyclodextrin, octakis(3,6-anhydro)- γ -cyclodextrin.

Typically, the per(3,6-anhydro)cyclodextrins of the alpha, beta or gamma cyclodextrins of the present invention may contain very small amounts of one non anhydrated glucopyranose units and tiny amounts of two non anhydrated glucopyranose units.

The amount of per(3,6-anhydro)cyclodextrin typically ranges from 0.0001 – 80% by weight of total composition, preferably from 0.001 – 70% by weight, more preferably from 0.01 – 65% and also from 0.1 – 60% by weight.

Compositions comprising a pharmaceutically effective drug, a peranhydrocyclodextrin and a carrier are not described in the art.

Accordingly, in a first aspect the present invention pertains to a pharmaceutical composition, comprising a pharmaceutically effective drug, a per(3,6-anhydro)cyclodextrin and a carrier. A preferred pharmaceutical composition is a pharmaceutical composition for topical administration. A more preferred is an ophthalmic composition.

The compositions of the present invention seem to have a high permeation facilitating efficacy as compared to the prior art compositions, such as for example hydroxypropyl-gamma-cyclodextrin.

Accordingly another object of this invention is the use of a peranhydrocyclodextrin as a permeation enhancer and/or drug transport enhancer, virtually through any mammal tissue. Accordingly, the peranhydrocyclodextrins are useful in the enhancement of the bioavailability of any pharmaceutically effective drug.

The invention pertains to the use of a per(3,6-anhydro)cyclodextrin to enhance drug permeation through cell membrane, wherein said membrane is preferably an ocular membrane, said drug being preferably administered topically to said cell membrane.

It further pertains to the use of a per(3,6-anhydro)cyclodextrin in the manufacture of a topical pharmaceutical medicament for the treatment of a disease being treatable by topical treatment, wherein said medicament comprises a per(3,6-anhydro)cyclodextrin, a carrier and a drug.

While applicant does not wish to be bound to any theory, applicant currently considers the following aspects regarding cell membrane permeation and the enhancement thereof:

The peranhydrocyclodextrins of the present invention may utilize cation binding cyclodextrins in order to alter normal physiological functions of membrane ion-channels and pumps, the cation-dependent energy sources resulting in an enhanced drug permeation across biological membranes.

It is currently believed in the art that all membrane transport processes require:

- permeability of the substance through the lipid bilayer , and
- availability of an energy source for transport

The latter factor appears to be related – among others, and as described in the state of the art - to Ca^{++} ions, since the Ca^{++} ATP-ase enzyme shall be an integral membrane protein participating in most of the membrane transport processes.

The lipid bilayer of biological membranes shall be intrinsically impermeable to ions and polar molecules. The permeability of such substances shall be conferred by two types of membrane proteins: the *pumps* and the *channels*.

Pumps seem to use a source of free energy (mainly from ATP, active transport) to transport ions.

The *channels* seem to allow the flow of ions rapidly across membranes. (e.g. passive transport)

Anhydro-cyclodextrin derivatives of the present invention (in its function as permeation enhancers) are speculated to affect these membrane protein-related transport processes resulting in enhanced drug transport through biological membranes.

The presence of anhydro cyclodextrins, moreover, may result in alteration of ion potentials in the outer surface of the membrane, thus changing the ion distribution in the extracellular and intracellular space. This could lead to the change of membrane physiological functions and hence may result in the observed enhanced transport.

As oral administration is the most common and convenient route of drug delivery, many strategies have been developed to tackle the various problems which are associated with poor oral bioavailability. Several approaches are known to improve the membrane permeation of hydrophilic or high molecular weight compounds, such as:

- Chemical modification of the molecular structure to increase lipophilicity;
- Reduction of the molecular weight of actives;
- Replacement of the hydrogen bonding groups in the actives;
- Co-administration of classic permeation enhancers (e.g. salicylate, EDTA, glucose) (Aungst, B.: J. Pharm. Sci. 1993. 82, 979-998); and
- Use of the prior art cyclodextrins (membrane lipid/CD interaction driven drug penetration).

Although these individual strategies are successfully applied to some drugs, a low oral bioavailability is very often the result of multiple factors and therefore, still requires a clear improvement.

The present invention offers a still further solution to the above by the use of a per-anhydro-cyclodextrins in a pharmaceutical composition.

Pharmaceutically active drugs of the present invention are typically selected from:

Anti-inflammatory drugs, such as steroids, e.g. dexamethasone, fluorometholone, hydrocortisone, prednisolone; or so-called non-steroidal anti-inflammatory drugs (NSAID) such as COX-inhibitors, e.g. diclofenac, ketorolac, or indomethacin;

Anti-allergic drugs, selected e.g. from FK506, 33-epi-chloro-33-desoxy-ascomycin (Elidel), cromolyn, emadine, ketotifen, levocabastine, lodoxamide, norketotifen, olopatadine, and rizabene,

Drugs to treat glaucoma (in particular intraocular pressure treatment), selected e.g. from latanoprost, 15-keto-latanoprost, unoprostone isopropyl, travaprost, betaxolol, clonidine, levobunolol and timolol;

Anti-infective drugs, e.g. selected from chloramphenicol, chlortetracycline, gentamycin, neomycin, ofloxacin, polymyxin B and tobramycin;

Antifungal drugs, e.g. selected from amphotericin B, fluconazole and natamycin;

Anti-viral drugs such as acyclovir, fomivirsen, ganciclovir, and trifluridine;

Anesthetic drugs, e.g. selected from cocaine hydrochloride, lidocaine and tetracaine hydrochloride;

Miotics, e.g. selected from carbachol, pilocarpine and physostigmine;

Carbonic anhydrase inhibitors, e.g. selected from acetazolamide and dorzolamide;

Alpha blocking agents, e.g. selected from apraclonidine and brimonidine; and

Antioxidants and/or vitamins, e.g. selected from retinol, retinol acetate, and retinol palmitate.

Combination of pharmaceutical active drugs may be used as well, such as for example ketotifen with one or more compounds selected from diclofenac, ketorolac, indomethacin, FK506, 33-epi-chloro-33-desoxy-ascomycin, cromolyn, emadine, levocabastine, lodoxamide, norketotifen, olopatadine, and rizabene.

As used herein, a pharmaceutically active drug is a drug in free form, in the form of a salt and/or as a mixture thereof.

The pharmaceutical compositions of this invention comprise, for example, enteral or parenteral administration forms from approximately 10 % to approximately 80 %, preferably from approximately 20 % to approximately 60 %, active ingredient (drug). Pharmaceutical compositions according to the invention for enteral or parenteral administration are, for example, in unit dose form, such as in the form of dragées, tablets, capsules or suppositories, and also ampoules. They are prepared in a manner known *per se*, for

example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes. For example, pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture or granules, if desired or necessary, after the addition of appropriate excipients, into tablets or dragée cores.

Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starch pastes using, for example, corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose and/or polyvinylpyrrolidone, if desired disintegrators, such as the above-mentioned starches, also carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Excipients are especially flow agents, flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Dragée cores are provided with suitable, optionally enteric, coatings, there being used, *inter alia*, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Dyes or pigments may be added to the tablets or dragée coatings, for example for identification purposes or to indicate different doses of active ingredient.

Other orally administrable pharmaceutical compositions are hard gelatin capsules and also soft, sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The hard gelatin capsules may comprise the active ingredient in the form of granules, for example in admixture with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilisers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, it likewise being possible for stabilisers to be added.

Suitable rectally administrable pharmaceutical compositions are, for example, suppositories that consist of a combination of the active ingredient with a suppository base material. Suitable suppository base materials are, for example, natural or synthetic triglycerides,

paraffin hydrocarbons, polyethylene glycols or higher alkanols. Gelatin rectal capsules that comprise a combination of the active ingredient with a base material may also be used. Suitable base materials include, for example, liquid triglycerides, polyethylene glycols and paraffin hydrocarbons.

There are suitable for parenteral administration by infusion and/or injection especially aqueous solutions of an active ingredient in water-soluble form, for example in the form of a water-soluble salt, and also suspensions of the active ingredient, such as corresponding oily suspensions, there being used suitable lipophilic solvents or vehicles, such as fatty oils, for example sesame oil, or synthetic fatty acid esters, for example ethyl oleate or triglycerides, or aqueous suspensions that comprise viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and optionally also stabilisers.

The compounds may also be administered topically in or around the eye, for example as eyedrops, ophthalmic suspensions or ointments, subconjunctival, peribulbar, retrobulbar or intravitreal injections, possibly with the use of slow-release devices, such as conjunctival inserts, microspheres or other periocular or intraocular depot devices.

Any other object of the present invention may be described only in any of the independent and / or dependant claims of the present application, and may therefore additionally form a basis for amending the present description.

Chemical Examples:

Example 1. Preparation of hexakis(3,6-anhydro)- α -cyclodextrin potassium chloride pentadecahydrate.

Freshly dried α -cyclodextrin (48.6 g, 0.050 mol) is dissolved in freshly opened dimethyl formamide (800 cm³) at room temperature. N-bromosuccinimide (142.4 g, 0.80 mol), and triphenylphosphine (148.6 g, 0.57 mol) is added in one portion to the solution at room temperature. The color of the reaction mixture becomes orange like as the TPP is added. The reaction temperature increases up to about 100 C at the end of TPP addition. The reaction mixture is immersed onto a pre-heated (60-70 C) oil-bath and stirred for 3 hrs at 80-85 C. When the reaction is completed, the reaction mixture is poured onto icy water (3000 cm³). Ultrasonicated for several minutes and allowed to stand for crystallization

(overnight). The yellow solid is filtered, washed with water (3 times 500 cm³, pH= 2-3, 3-4, 4-5), dried under reduced pressure (5-10 kPa at moderate temperature (40-45 C) in the presence of P₂O₅. The obtained solid (250.6 g) contains TPPO and brominated α -cyclodextrins. The product is used for the preparation of anhydro- α -cyclodextrin without further purification.

Potassium hydroxide (112.2 g, 2.0 mol) is dissolved in 3:1 MeOH/H₂O (1500 cm³) at room temperature and tetrabromo- α -cyclodextrin (250.6 g) is added spoonwise without additional cooling. The color of the reaction mixture disappears, then becomes opaque or precipitation is formed, the re-dissolution of the solid is observed and the solution again becomes yellow, which turns to brown upon elongated heating. The reaction is practically complete as the addition is finished. After 60 min the reaction mixture is cooled, stirrer is removed and methanol is removed by evaporation. When the methanol is removed, 200 cm³ water is added. As the reaction mixture is free from MeOH, cooled to room temperature and neutralized (pH: ~5.5) by cc. HCl. Charcoal is added to the suspension (20 g), and stirred for 1 hr. Filtered and washed with water (3 times 40 cm³), and water is removed by freeze-drying (25 C/0.06-0.1 Pa). The obtained solid (light brown solid 220 g), contains KCl and KBr. TLC has few information about the composition due to the high inorganic salt content. The obtained product (220 g) is refluxed with MeOH (550 cm³) for 30 min, and allowed to stand for crystallization (overnight).

The precipitate is filtered off, washed with MeOH (2*100 cm³) and MeOH is removed by evaporation (55-60 C/10-15 kPa then 95-100 C/0.05-0.1 kPa, dark brown solid foam 29.8 g). The solid obtained from the evaporation (59.6 g) is dissolved in water (1200 cm³). The pH of the solution is adjusted (pH:8.7 => 5.5) with 1 N HCl (62 cm³) and clarified with charcoal (15 g) stirred at 25 C (overnight), filtered, washed with water (3 times 100 cm³) and water was removed (58 g, 40 C/1-2 kPa, then 95-100 C/1-2 kPa). The obtained oil is dissolved in water (60 cm³) and allowed to crystallize. Filtration resulted in white, crystalline material (11.2 g) with KCl content < 11 %, and water content < 30.0 %, Mp: 246-247 C [dec], $[\alpha]_D^{25} = -73.5$ (air-dry substance), conductivity of 1 aq. solution: ~1100 μ S/cm.

Example 2. Preparation of hexakis(3,6-anhydro)- α -cyclodextrin.

Hexakis(6-deoxy-6-bromo)- α -cyclodextrin (15.1 g, 0.01 mol) is suspended in 3:1 MeOH/H₂O (1500 cm³) at room temperature and lithium hydroxide (10.0 g, 0.4 mol) was added and

heated to reflux. When the reaction is completed (approx. 20 hrs), the reaction mixture is cooled by addition of dry-ice. The formed lithium carbonate is filtered off, and solvents are removed by evaporation. The obtained solid is treated with acetone (100 cm³), then dissolved in methanol (100 cm³) and ions are removed by addition of strong anion- (25 g) then cation-exchanger (40 g). The ion-free solution is clarified by charcoal (2 g) and removal of methanol resulted in almost white solid (3.0 g). Mp: 230-235 C, $[\alpha]_D^{25} = -82.5$ (air-dry substance), conductivity of 1 aq. solution: ~25 $\mu\text{S}/\text{cm}$.

Example 3. Preparation of heptakis(3,6-anhydro)- β -cyclodextrin

Freshly dried β -cyclodextrin (22.7 g, 0.020 mol) is dissolved in freshly opened dimethyl formamide (400 cm³) at room temperature. Iodine (81.2 g, 0.32 mol), and triphenylphosphine (78.2 g, 0.30 mol) is added in one portion to the solution at room temperature with additional external cooling. The reaction temperature heated up to about 80 C, and stirred for 4 hrs at 80-85 C. When the reaction is completed, the major part of DMF is removed by distillation, than poured onto methanol (2000 cm³), and allowed to crystallize 1 week, room temperature). The yellow solid is filtered, washed with methanol (3*200 cm³), dried under reduced pressure (5-10 kPa at moderate temperature (40-45 C) in the presence of P₂O₅. The obtained solid (34.3 g, 90 % theor. yield) does not contain TPPO.

Heptakis(6-deoxy-6-iodo)- β -cyclodextrin (10.8 g, 0.005 mol) is dissolved in dimethyl sulfoxide, and sodium hydroxide (7.0 g, 0.175 mol) is added at stirred for 10 hrs at 70 C. The reaction mixture is cooled to room temperature and treated with ion-exchangers (100 g of strong anion- and 100 g of strong cation-exchanger), ionexchangers are removed by filtration, washed with DMSO (3 times 100 cm³), then DMSO is removed *in vacuo*, and the obtained waxy solid was treated with acetone. Solid is filtered off and washed with acetone (pale yellow, 4.8 g). Mp: 230-235 C, $[\alpha]_D^{25} = -85.5$ (air-dry substance), conductivity of 1 aq. solution: ~20 $\mu\text{S}/\text{cm}$.

Example 4. Preparation of octakis(3,6-anhydro)- γ -cyclodextrin

Freshly dried γ -cyclodextrin (25.9 g, 0.020 mol) is dissolved in freshly opened dimethyl formamide (400 cm³) at room temperature. N-bromosuccinimide (57.0 g, 0.32 mol), and

triphenylphosphine (78.2 g, 0.30 mol) is added in one portion to the solution at room temperature. The color of the reaction mixture becomes orange like as the TPP is added. The reaction temperature increases up to about 60 C at the end of TPP addition. The reaction mixture is immersed onto a pre-heated (70-80 C) oil-bath and stirred for 4 hrs at 80-85 C. When the reaction is completed, the reaction mixture is poured onto icy water (3000 cm³). Ultrasonicated for several minutes and allowed to stand for crystallization (overnight). The yellow solid is filtered, washed with water (3 times 200 cm³, pH= 2-3, 3-4, 4-5), dried under reduced pressure (5-10 kPa at moderate temperature (40-45 C) in the presence of P₂O₅. The obtained solid (229 g) contains TPPO and brominated γ -cyclodextrins. The product is dissolved in methanol and the pH of the solution is adjusted to pH 9-10 with sodium methoxide. The pH-shift results in crystalline precipitation of the product. The crystalline material is removed by filtration (28.8 g, 80 % theor. yield). Octakis(6-deoxy-6-bromo)- γ -cyclodextrin (10.8 g, 0.006 mol) is dissolved in dimethyl sulfoxide, and lithium hydroxide (6.0 g, 0.24 mol) is added at stirred for 10 hrs at 70 C. The reaction mixture is cooled to room temperature and treated with ion-exchangers (100 g of strong anion- and 100 g of strong cation-exchanger), ion-exchangers are removed by filtration, washed with DMSO (3 times 100 cm³), then DMSO is removed *in vacuo*, and the obtained waxy solid was treated with acetone. Solid is filtered off and washed with acetone (pale yellow, 4.3 g). Mp: 230-235 C, $[\alpha]_D^{25} = -92.5$ (air-dry substance), conductivity of 1 aq. solution: ~10 μ S/cm.

Biological Examples:

Corneal permeation experiments with diclofenac (Voltaren) formulations

1) Diclofenac 0.1% without thiomersal (similar to marketed Voltaren Ophtha formulation, SDU)

Time (min)	Average permeated amount (microgram)	S.D.
0	0.00	0.00
30	0.00	0.00
60	0.00	0.00
90	0.22	0.2
120	0.69	0.42
180	1.98	0.88

2) Diclofenac 0.1% with 2% HP- γ -CD and without BAC

Time (min)	Average permeated amount (microgram)	S.D.
0	0.00	0.00
30	0.00	0.00
60	0.25	0.24
90	1.22	0.53
120	2.25	0.71
180	6.43	1.64

3) Diclofenac 0.1% with 2% hexakis-(3,6-anhydro)-alpha-CD and without BAC

Time (min)	Average permeated amount (microgram)	S.D.
0	0.00	0.00
30	1.15	1.73
60	6.11	2.92
90	10.51	2.90
120	16.45	3.36
180	28.41	4.39

4) Diclofenac 0.1% with 2% heptakis-(3,6-anhydro)-beta-CD and without BAC

Time (min)	Average permeated amount (microgram)	S.D.
0	0.00	0.00
30	0.13	0.28
60	5.45	1.75
90	12.08	2.85
120	20.42	3.49
180	35.33	3.74

5) Diclofenac 0.1% with 2% octakis-(3,6-anhydro)-gamma-CD and without BAC

Time (min)	Average permeated amount (microgram)	S.D.
0	0.00	0.00
30	0.00	0.00
60	1.76	0.33
90	4.97	0.68
120	8.12	1.02
180	14.50	1.58

BAC = benzalkonium chloride

HP-gamma-CD = hydroxypropyl- γ -cyclodextrin

QA- β -CD: quaternary ammonium beta-cyclodextrin

In the above experiments [item 2) & item 3, 4 and 5)] the efficacy in drug permeation is directly comparable with respect to the prior art situation (HP-gamma-CD) and embodiments of this invention, namely hexakis-(3,6-anhydro)-alpha-CD, heptakis-(3,6-anhydro)-beta-CD and octakis-(3,6-anhydro)-gamma-CD.

Claims:

1. A pharmaceutical composition comprising a per(3,6-anhydro)cyclodextrin, a pharmaceutically active drug and a carrier.
2. Composition of claim 1, wherein said per(3,6-anhydro)cyclodextrin is selected from the group consisting of hexakis(3,6-anhydro)- α -cyclodextrin, heptakis(3,6-anhydro)- β -cyclodextrin, octakis(3,6-anhydro)- γ -cyclodextrin, and mixtures thereof.
3. Composition of claim 1, wherein composition is adapted to topical administration.
4. Composition of claim 1, wherein the amount of said per(3,6-anhydro)cyclodextrin is in a range of from 0.01 – 80% by weight of total composition.
5. Composition of claim 3, which is an ophthalmic composition.
6. Use of a per(3,6-anhydro)cyclodextrin to enhance drug permeation through cell membrane, wherein said membrane is preferably an ocular membrane, said drug being preferably administered topically to said cell membrane.
7. Use of a per(3,6-anhydro)cyclodextrin in the manufacture of a topical pharmaceutical medicament for the treatment of a disease being treatable by topical treatment, wherein said medicament comprises a per(3,6-anhydro)cyclodextrin, a carrier and a drug.
8. A method of improving drug permeability through (mammalian) tissue (through cell membrane), which method comprises the steps of:
Conventionally admixing an effective amount of a per(3,6-anhydro)cyclodextrin, an effective amount of a drug, a carrier, and optionally one or more further ingredients selected from the group of buffers, tonicity enhancing agents, preservatives, solubilizers, stabilizers/solubilizers, and complexing agents; and
administering said pharmaceutical composition comprising said per(3,6-anhydro)cyclodextrin to said tissue.

9. Method of claim 8, wherein said tissue is selected from mucus tissue and ocular tissue, such as corneal epithelial cells and conjunctival cells.

10. Method of improving drug permeability in ocular tissue, which method comprises the topical administration of an effective amount of an ophthalmic drug in appropriate admixture with a per(3,6-anhydro)cyclodextrin to the ocular tissue of a patient in need of such treatment.

Abstract

The present invention relates to a pharmaceutical composition comprising a peranhydro-cyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.